Maravai LifeSciences Holdings, Inc.
$3.61
▲
2.79%
2026-04-21 08:15:00
www.maravai.com
NMS: MRVI
Explore Maravai LifeSciences Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$928.01 M
Current Price
$3.61
52W High / Low
$4.11 / $1.67
Stock P/E
—
Book Value
$1.46
Dividend Yield
—
ROCE
-17.71%
ROE
-48.59%
Face Value
—
EPS
$-0.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
435
Beta
0.43
Debt / Equity
97.85
Current Ratio
6.6
Quick Ratio
5.69
Forward P/E
-20.8
Price / Sales
6.08
Enterprise Value
$757.55 M
EV / EBITDA
-10.22
EV / Revenue
4.08
Rating
Buy
Target Price
$4.33
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 2. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 3. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 4. | Propanc Biopharma, Inc. | $0.12 | — | $2.33 M | — | -407.57% | -18.12% | $11 / $0.1 | $0.78 |
| 5. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 6. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 7. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 49.87 M | 41.63 M | 47.4 M | 46.85 M | 56.41 M |
| Operating Profit | -22.53 M | -33.59 M | -35.69 M | -36.73 M | -26.84 M |
| Net Profit | -35.68 M | -25.56 M | -39.59 M | -29.95 M | -26.14 M |
| EPS in Rs | -0.24 | -0.17 | -0.27 | -0.2 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 185.74 M | 259.19 M | 288.94 M | 883 M |
| Operating Profit | -128.53 M | -72.68 M | -28.47 M | 566.42 M |
| Net Profit | -130.77 M | -144.85 M | -119.03 M | 220.21 M |
| EPS in Rs | -0.89 | -0.99 | -0.81 | 1.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 770.58 M | 1.01 B | 1.49 B | 2.28 B |
| Total Liabilities | 397.87 M | 431.04 M | 697.57 M | 1.38 B |
| Equity | 212.38 M | 325.29 M | 416.75 M | 545.22 M |
| Current Assets | 296.25 M | 429.15 M | 699.91 M | 847.9 M |
| Current Liabilities | 44.92 M | 56.97 M | 87.47 M | 110.14 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -57.57 M | 7.46 M | 126.22 M | 535.98 M |
| Investing CF | -31.41 M | -24.32 M | -122.31 M | -267.61 M |
| Financing CF | -16.5 M | -235.71 M | -61.09 M | -187.5 M |
| Free CF | -70.72 M | -22.19 M | 60.67 M | 518.89 M |
| Capex | -13.15 M | -29.66 M | -65.55 M | -17.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -10.3% | -67.28% | — | — |
| Earnings Growth % | -21.69% | -154.05% | — | — |
| Profit Margin % | -55.89% | -41.19% | 24.94% | — |
| Operating Margin % | -28.04% | -9.85% | 64.15% | — |
| Gross Margin % | 41.79% | 48.52% | 80.87% | — |
| EBITDA Margin % | -60.54% | 246.56% | 69.08% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.